Deutsche Bank set a €70.00 ($81.40) target price on Bayer (FRA:BAYN) in a report issued on Thursday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
BAYN has been the topic of a number of other reports. Societe Generale set a €65.00 ($75.58) price target on Bayer and gave the company a neutral rating in a research report on Wednesday, March 27th. UBS Group set a €110.00 ($127.91) price target on Bayer and gave the company a buy rating in a research report on Monday, February 4th. DZ Bank reiterated a buy rating on shares of Bayer in a research report on Monday, March 11th. Baader Bank set a €123.00 ($143.02) price target on Bayer and gave the company a buy rating in a research report on Friday, January 18th. Finally, Nord/LB set a €72.00 ($83.72) price target on Bayer and gave the company a neutral rating in a research report on Wednesday, February 27th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of Hold and an average price target of €81.80 ($95.12).
Shares of FRA:BAYN opened at €61.16 ($71.12) on Thursday. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: What is systematic risk?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.